<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535986</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-CO-301</org_study_id>
    <nct_id>NCT04535986</nct_id>
  </id_info>
  <brief_title>A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD</brief_title>
  <official_title>A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ensifentrine is safe and effective for the&#xD;
      treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of Average forced expiratory volume in 1 second (FEV1) area under the curve (AUC)0-12h</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average FEV1 AUC0-4h post-dose at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of Average FEV1 AUC0-4h post-dose at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 over 4 hours post dose at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in Peak FEV1 over 4 hours post dose at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline as a weekly average of Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) total score at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline of SGRQ total score at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning trough FEV1 at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of Morning trough FEV1 at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of St. George's Respiratory Questionnaire (SGRQ) responders at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline of Rescue medication use at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transitional Dyspnea Index (TDI) at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Transitional Dyspnea Index (TDI) at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening trough FEV1 at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline Evening trough FEV1 at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 at Week 6 and Week 24</measure>
    <time_frame>6 and 24 weeks</time_frame>
    <description>Change from baseline Peak FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning trough FEV1 at Week 6 and Week 24</measure>
    <time_frame>6 and 24 weeks</time_frame>
    <description>Change from baseline morning trough FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening trough FEV1 at Week 6 and Week 24</measure>
    <time_frame>6 and 24 weeks</time_frame>
    <description>Change from baseline evening trough FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-4h at Week 6 and Week 24</measure>
    <time_frame>6 and 24 weeks</time_frame>
    <description>Change from baseline FEV1 AUC0-4h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating-Respiratory Symptoms (E-RS) Total Score at Week 6 and Week 12</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Change from baseline E-RS Total Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) responder analysis at Week 6 and Week 12</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <description>Change from baseline SGRQ responder analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDI at Week 6 and Week 12</measure>
    <time_frame>6 and 12 Weeks</time_frame>
    <description>Change from baseline TDI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Respiratory Questionnaire (SGRQ) total score at Weeks 6 and 12</measure>
    <time_frame>6 Weeks and 12 weeks</time_frame>
    <description>Change from baseline of SGRQ total score at Weeks 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication use at Weeks 6 and 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline of Rescue medication use at Weeks 6 and 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ensifentrine Nebulized Suspension; 3 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Nebulized BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ensifentrine</intervention_name>
    <description>• Dosage Formulation: Ensifentrine Nebulizer suspension&#xD;
Dosage 3mg&#xD;
Frequency: Twice Daily&#xD;
Study to randomize 800 patients in total&#xD;
Subjects randomized to the 24-week subset will enroll 400 patients (1:1 ensifentrine (3 mg): placebo)&#xD;
Subjects randomized to the 48-week subset will enroll approximately 400 patients randomized 3:1 ensifentrine (3 mg): placebo.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>• Dosage Formulation: Ensifentrine Nebulizer suspension&#xD;
Dosage 3mg&#xD;
Frequency: Twice Daily&#xD;
Study to randomize 800 patients in total&#xD;
Subjects randomized to the 24-week subset will enroll 400 patients (1:1 ensifentrine (3 mg): placebo)&#xD;
Subjects randomized to the 48-week subset will enroll approximately 400 patients randomized 3:1 ensifentrine (3 mg): placebo.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Informed Consent&#xD;
&#xD;
          1. Capable of giving informed consent indicating that they understand the purpose of the&#xD;
             study and study procedures and agree to comply with the requirements and restrictions&#xD;
             listed in the informed consent form (ICF).&#xD;
&#xD;
             Age and Sex&#xD;
&#xD;
          2. Age: Patient must be 40 to 80 years of age inclusive, at the time of Screening.&#xD;
&#xD;
          3. Sex:&#xD;
&#xD;
               -  Males are eligible to participate if they agree to use contraception as described&#xD;
                  in the contraceptive guidance from Screening and throughout the study and for at&#xD;
                  least 30 days after the last dose of blinded study medication.&#xD;
&#xD;
               -  Females are eligible to participate if they are not pregnant, not breastfeeding,&#xD;
                  and at least one of the following conditions apply:&#xD;
&#xD;
                    1. Not a woman of childbearing potential (WOCBP) as defined in Or&#xD;
&#xD;
                    2. A WOCBP who agrees to follow the contraceptive guidance from Screening and&#xD;
                       throughout the study and for at least 30 days after the last dose of blinded&#xD;
                       study medication.&#xD;
&#xD;
             Smoking History&#xD;
&#xD;
          4. Smoking History: Current or former cigarette smokers with a history of cigarette&#xD;
             smoking ≥10 pack years at Screening (Visit 0) [number of pack years = (number of&#xD;
             cigarettes per day / 20) × number of years smoked (eg, 20 cigarettes per day for 10&#xD;
             years, or 10 cigarettes per day for 20 years)]. Pipe and/or cigar use cannot be used&#xD;
             to calculate pack-year history. Former smokers are defined as those who have stopped&#xD;
             smoking for at least 6 months prior to Visit 0. Smoking cessation programs are&#xD;
             permitted during the study.&#xD;
&#xD;
             COPD Diagnosis, Symptoms, Severity and Maintenance Therapy&#xD;
&#xD;
          5. COPD Diagnosis: Patients with an established clinical history of COPD as defined by&#xD;
             the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with&#xD;
             symptoms compatible with COPD.&#xD;
&#xD;
          6. COPD Symptoms: A score of ≥2 on the Modified Medical Research Council (mMRC) Dyspnea&#xD;
             Scale.&#xD;
&#xD;
          7. COPD Severity:&#xD;
&#xD;
               1. Pre- and Post-albuterol/salbutamol FEV1/FVC ratio of &lt;0.70.&#xD;
&#xD;
               2. Post-albuterol/salbutamol FEV1 ≥30 % and ≤70% of predicted normal calculated&#xD;
                  using the National Health and Nutrition Examination Survey III.&#xD;
&#xD;
          8. Maintenance Therapy: Patients on no maintenance/background therapy or patients on&#xD;
             stable maintenance LAMA or LABA therapy are eligible. Patients taking maintenance LAMA&#xD;
             or LABA therapy must demonstrate stable use of the maintenance LAMA or LABA therapy&#xD;
             for at least 3 months prior to Screening and agree to continue use for the duration of&#xD;
             the study. Background maintenance LAMA or LABA bronchodilator therapy will be capped&#xD;
             at 50% of patients.&#xD;
&#xD;
             Other Requirements for Inclusion&#xD;
&#xD;
          9. Capable of withholding SABAs for 4 hours prior to initiation of any spirometry.&#xD;
             Patients in the maintenance LAMA or LABA therapy stratum must be capable of&#xD;
             withholding Twice-Daily maintenance LAMA or LABA for 24 hours and Once-Daily&#xD;
             maintenance LAMA or LABA for 48 hours prior to initiation of any spirometry.&#xD;
&#xD;
         10. Capable of using the study nebulizer correctly and complying with all study&#xD;
             restrictions and procedures.&#xD;
&#xD;
         11. Ability to perform acceptable spirometry in accordance with ATS/ERS guidelines.&#xD;
&#xD;
        Inclusion Criteria at Randomization (RPL554-CO-301)&#xD;
&#xD;
          1. Symptoms of COPD: A score of ≥2 on the mMRC Dyspnea Scale.&#xD;
&#xD;
          2. Completion of the e-Diary at least 5 of the last 7 days of the Run-in period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Current Condition or Medical History&#xD;
&#xD;
          1. History of life-threatening COPD including Intensive Care Unit admission and/or&#xD;
             requiring intubation.&#xD;
&#xD;
          2. Hospitalizations for COPD, pneumonia, or Corona Virus Disease 2019 (COVID-19) in the&#xD;
             12 weeks prior to Screening and/or a positive COVID-19 test result indicating an&#xD;
             active infection at Screening. Patients with COVID-19 antibodies from a previous&#xD;
             exposure with no active infection are not excluded.&#xD;
&#xD;
          3. COPD exacerbation requiring oral or parenteral steroids within 3 months of Screening.&#xD;
&#xD;
          4. Previous lung resection or lung reduction surgery within 1-year of Screening.&#xD;
&#xD;
          5. Long term oxygen use defined as oxygen therapy prescribed for greater than 12 hours&#xD;
             per day. As needed oxygen use (≤12 hours per day) is not exclusionary.&#xD;
&#xD;
          6. Pulmonary rehabilitation, unless such treatment has been in a stable maintenance phase&#xD;
             for 4 weeks prior to Visit 1 and remains stable during the study.&#xD;
&#xD;
          7. Lower respiratory tract infection within 6 weeks of Screening.&#xD;
&#xD;
          8. Other respiratory disorders including, but not limited to, a current diagnosis of&#xD;
             asthma, active tuberculosis, lung cancer, sarcoidosis, lung fibrosis, interstitial&#xD;
             lung diseases, unstable sleep apnea, known alpha-1 antitrypsin deficiency, core&#xD;
             pulmonale, clinically significant pulmonary hypertension, clinically significant&#xD;
             bronchiectasis, or other active pulmonary diseases.&#xD;
&#xD;
          9. Major surgery (requiring general anesthesia) in the 6 weeks prior to Screening, lack&#xD;
             of full recovery from surgery at Screening, or planned surgery through the end of the&#xD;
             study.&#xD;
&#xD;
         10. Historical or current evidence of clinically significant cardiovascular disease&#xD;
             defined as any disease that in the opinion of the Investigator would put the safety of&#xD;
             the patient at risk through participation or which could affect the efficacy or safety&#xD;
             analysis if the disease/condition were to exacerbate during the study, including, but&#xD;
             not limited to:&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months prior to Screening.&#xD;
&#xD;
               -  Unstable or life-threatening cardiac arrhythmia requiring intervention within 3&#xD;
                  months prior to Screening.&#xD;
&#xD;
               -  Diagnosis of New York Heart Association Class III and Class IV heart failure.&#xD;
&#xD;
         11. Chronic uncontrolled disease including, but not limited to, endocrine, active&#xD;
             hyperthyroidism, neurological, hepatic, gastrointestinal, renal, hematological,&#xD;
             urological, immunological, psychiatric, or ophthalmic diseases that the Investigator&#xD;
             believes are clinically significant.&#xD;
&#xD;
         12. Unstable liver disease defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice,&#xD;
             cirrhosis, known biliary abnormalities (except for Gilbert's syndrome or asymptomatic&#xD;
             gallstones).&#xD;
&#xD;
         13. History of or current malignancy of any organ system, treated or untreated within the&#xD;
             past 5 years, except for localized basal or squamous cell carcinoma of the skin.&#xD;
&#xD;
         14. Findings on physical examination that an investigator considers to be clinically&#xD;
             significant at Screening.&#xD;
&#xD;
             Prior/Concomitant Therapy&#xD;
&#xD;
         15. Use of prohibited medications within the time intervals.&#xD;
&#xD;
             History or Suspicion of Drug or Alcohol Abuse&#xD;
&#xD;
         16. Current or history of past drug or alcohol abuse within the past 5 years.&#xD;
&#xD;
             Laboratory and Other Diagnostic Parameters&#xD;
&#xD;
         17. Glomerular Filtration Rate (eGFR) &lt;30 mL/min. The Chronic Kidney Disease Epidemiology&#xD;
             Collaboration Creatinine (2009) calculation will be used (Levey, 2009).&#xD;
&#xD;
         18. Alanine aminotransferase (ALT) ≥ 2 x upper limit of normal (ULN), alkaline phosphatase&#xD;
             and/or bilirubin &gt; 1.5 x ULN (isolated bilirubin &gt;1.5 x ULN is acceptable if bilirubin&#xD;
             is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
         19. Hepatitis B antibody:&#xD;
&#xD;
               -  Positive findings for both Hepatitis B surface antigen (HBsAg) and Hepatitis B&#xD;
                  core antibody (anti-HBc) are excluded, as this indicates acute or chronic&#xD;
                  infection.&#xD;
&#xD;
               -  Negative findings for HBsAg and Hepatitis B surface antibody (anti-HBs) but&#xD;
                  positive findings for anti-HBc are excluded as this may indicate current or&#xD;
                  resolving infection.&#xD;
&#xD;
               -  Positive findings for anti-HBc and anti-HBs but negative findings for HBsAg are&#xD;
                  not excluded, as this indicates immunity due to natural infection.&#xD;
&#xD;
               -  Positive findings for anti-HBs but negative findings for HBsAg and anti-HBc are&#xD;
                  not excluded, as this indicates immunity due to hepatitis B vaccination.&#xD;
&#xD;
         20. Hepatitis C antibody positive.&#xD;
&#xD;
         21. Any other abnormal hematology, biochemistry, or viral serology deemed by an&#xD;
             investigator to be clinically significantly abnormal. Abnormal chemistry and/or&#xD;
             hematology may be repeated during Screening.&#xD;
&#xD;
         22. Chest X-ray (CXR; posterior-anterior) at Screening, or in the 12 months prior to&#xD;
             Screening with clinically significant abnormalities not attributable to COPD. If a CXR&#xD;
             within the past 12 months is not available but a computerized tomography (CT) scan&#xD;
             within the same time period is available, the CT scan may be reviewed in place of a&#xD;
             CXR. For subjects in Germany, if a CXR or CT scan is not available in the 12 months&#xD;
             prior to Screening, the subject is not eligible for the study.&#xD;
&#xD;
         23. Electrocardiogram (ECG) finding that is significantly abnormal on the 12-lead ECG&#xD;
             obtained at Screening.&#xD;
&#xD;
             Other Exclusions&#xD;
&#xD;
         24. Use of an experimental drug within 30 days or 5 half-lives of Screening, whichever is&#xD;
             longer, and/or participation in a study treatment-free follow-up phase of a clinical&#xD;
             study within 30 days prior to Screening.&#xD;
&#xD;
         25. Use of an experimental medical device or participation in a follow-up phase of an&#xD;
             experimental medical device clinical study within 30 days prior to Screening.&#xD;
&#xD;
         26. Intolerance or hypersensitivity to albuterol/salbutamol or ensifentrine (RPL554) or&#xD;
             any of its excipients/components.&#xD;
&#xD;
         27. Prior receipt of blinded study medication in an ensifentrine (RPL554) study.&#xD;
&#xD;
         28. Affiliation with the investigator site, including an Investigator, Sub-Investigator,&#xD;
             study coordinator, study nurse, other employee of participating investigator or study&#xD;
             site or a family member of the aforementioned.&#xD;
&#xD;
         29. Inability to read, understand, and/or complete questionnaires (in the opinion of the&#xD;
             Investigator).&#xD;
&#xD;
         30. A disclosed history or one known to the Investigator of significant non-compliance in&#xD;
             previous investigational studies or with prescribed medications.&#xD;
&#xD;
         31. Any other reason that the Investigator considers makes the patient unsuitable to&#xD;
             participate.&#xD;
&#xD;
        Exclusion Criteria at Randomization (RPL554-CO-301)&#xD;
&#xD;
          1. COPD exacerbation or lower respiratory tract infection between Screening and&#xD;
             Randomization (defined as use of any additional treatment other than current treatment&#xD;
             and rescue medication and/or emergency department or hospital visit). Patients with a&#xD;
             severe COPD exacerbation that requires hospitalization may not be rescreened.&#xD;
&#xD;
          2. Positive COVID-19 result at Screening or between Screening and Randomization.&#xD;
&#xD;
          3. Prohibited medication use between Screening Visit 0 and Visit 1.&#xD;
&#xD;
          4. Significantly abnormal ECG finding on the 12-lead ECG obtained at Screening as&#xD;
             assessed by the investigator or site medical doctor/medically qualified person or on&#xD;
             the pre-dose (prior to randomization) ECG obtained at Visit 1.&#xD;
&#xD;
             In the event that the central ECG reviewer discovers a significant ECG abnormality on&#xD;
             the Visit 1 ECG, the patient will be discontinued.&#xD;
&#xD;
          5. Did not meet one or more of the Inclusion Criteria or met one or more of the Exclusion&#xD;
             Criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margot Macdonald-Berko</last_name>
    <phone>6464130307</phone>
    <email>Margot.Macdonald-Berko@veronapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Medical Group</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Orr, DO</last_name>
      <phone>623-815-9800</phone>
      <email>rorr@phoenixmedicalgroup.com</email>
    </contact>
    <investigator>
      <last_name>Robert Orr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMR Tempe</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Anderson, MD</last_name>
      <phone>602-910-3343</phone>
      <email>corey.anderson@amrllc.com</email>
    </contact>
    <investigator>
      <last_name>Corey Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beach Physicians Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bassil Aish, MD</last_name>
      <phone>714-848-1655</phone>
      <email>bassilaish@aol.com</email>
    </contact>
    <investigator>
      <last_name>Bassil Aish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Averill, MD</last_name>
      <phone>727-210-4606</phone>
      <email>faverillresearch@stfrancismed.com</email>
    </contact>
    <investigator>
      <last_name>Francis Averill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qway Research, LLC</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fausto Castillo, MD</last_name>
      <phone>305-884-0134</phone>
      <email>castillo@qwayresearch.com</email>
    </contact>
    <investigator>
      <last_name>Fausto Castillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multi-Specialty Research Associates, Inc.</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Strauss, DO</last_name>
      <phone>386-438-8977</phone>
      <email>drstrauss@msrainc.com</email>
    </contact>
    <investigator>
      <last_name>Guy Strauss, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelio Torres Consuegra, MD</last_name>
      <phone>305-262-3396</phone>
      <email>atorres@eliteclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Aurelio Torres Consuegra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Global Research Solutions Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Hegedosh, MD</last_name>
      <phone>954-634-7047</phone>
      <email>nhegedoshmd@globalresearchus.com</email>
    </contact>
    <investigator>
      <last_name>Natalia Hegedosh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phoenix Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Birriel, MD</last_name>
      <phone>608-848-8900</phone>
      <email>josebirriel@researchphoenixmedical.com</email>
    </contact>
    <investigator>
      <last_name>Jose Birriel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Haffizulla, MD</last_name>
      <phone>954-915-9991</phone>
      <email>jhaffizulla@pcrflorida.com</email>
    </contact>
    <investigator>
      <last_name>Jason Haffizulla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimball Johnson, MD</last_name>
      <phone>404-537-1281</phone>
      <email>drjohnson@iresearchatlanta.com</email>
    </contact>
    <investigator>
      <last_name>Kimball Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>In-Quest Medical Research, LLC</name>
      <address>
        <city>Peachtree Corners</city>
        <state>Georgia</state>
        <zip>30071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suresh Shah, MD</last_name>
      <phone>770-903-0148</phone>
      <email>drshah@inquestmed.com</email>
    </contact>
    <investigator>
      <last_name>Suresh Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Rincon</city>
        <state>Georgia</state>
        <zip>31326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Mascolo, MD</last_name>
      <phone>912-303-5983</phone>
      <email>mmascolo@iacthealth.com</email>
    </contact>
    <investigator>
      <last_name>Maria Mascolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wise, MD</last_name>
      <phone>410-550-0545</phone>
      <email>rwise@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Wise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Research Institute of SE Michigan</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Ferguson, MD</last_name>
      <phone>248-478-6561</phone>
      <email>garytferguson@msn.com</email>
    </contact>
    <investigator>
      <last_name>Gary Ferguson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Clinical Research Center, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Tillinghast, MD</last_name>
      <phone>314-514-8509</phone>
      <email>j.tillinghast@clinicalresearchcenter.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Tillinghast, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sierra Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naresh Singh, MD</last_name>
      <phone>702-384-5101</phone>
      <email>singh@sieraclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Naresh Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jacobs, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IMA Clinical Research, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Greenwald, MD</last_name>
      <phone>646-722-6214</phone>
      <phone_ext>708</phone_ext>
      <email>James.Greenwald@ima-us.com</email>
    </contact>
    <investigator>
      <last_name>James Greenwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crisor, LLC - Grants Pass</name>
      <address>
        <city>Grants Pass</city>
        <state>Oregon</state>
        <zip>97527</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Parks, MD</last_name>
      <phone>541-858-1018</phone>
      <phone_ext>0</phone_ext>
      <email>kparks@velocityclinical.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Parks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Central PA, LLC</name>
      <address>
        <city>DuBois</city>
        <state>Pennsylvania</state>
        <zip>15801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Bansal, MD</last_name>
      <phone>814-940-1212</phone>
      <email>bansalmd@clinicalresearchassoc.com</email>
    </contact>
    <investigator>
      <last_name>Sandeep Bansal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Physicians, Emphysema/COPD Research Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Sciurba, MD</last_name>
      <phone>412-648-6494</phone>
      <email>sciurbafc@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Frank Sciurba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medtrial</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Mitchell, MD</last_name>
      <phone>803-254-4295</phone>
      <email>cmitchellmd@medtrialsc.com</email>
    </contact>
    <investigator>
      <last_name>Carl Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MDFirst Research</name>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <zip>29720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amrendra Kumar, MD</last_name>
      <phone>704-491-1102</phone>
      <email>akumar@mdfirstresearch.com</email>
    </contact>
    <investigator>
      <last_name>Amrendra Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga Research &amp; Medicine (CHARM)</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Ryan, MD</last_name>
      <phone>423-643-2253</phone>
      <email>eryan68@epbfi.com</email>
    </contact>
    <investigator>
      <last_name>Eugene Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Services</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar DeValle, MD</last_name>
      <phone>281-738-2642</phone>
      <email>odevalle@whcrs.com</email>
    </contact>
    <investigator>
      <last_name>Oscar DeValle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Research of Abingdon, LLC</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emory Robinette, MD</last_name>
      <phone>276-619-8367</phone>
      <email>researchpi@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Emory Robinette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TPMG Clinical Research Williamsburg</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Subramaniam, MD</last_name>
      <phone>757-707-3503</phone>
      <email>vijay-research@tpmgpc.com</email>
    </contact>
    <investigator>
      <last_name>Vijay Subramaniam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SHATPPD - Haskovo, EOOD</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veselin Kalfov, MD</last_name>
      <phone>+359888727511</phone>
      <email>kalfov@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Veselin Kalfov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Hera EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1510</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiril Palaveev, MD</last_name>
      <phone>+35929310293</phone>
      <email>palaveevk@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Kiril Palaveev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MC &quot;Sv. Ivan Rilski&quot;, OOD</name>
      <address>
        <city>Vidin</city>
        <zip>3700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivo Iliev, MD</last_name>
      <phone>+35994607655</phone>
      <email>ivo_pulmo@mail.bg</email>
    </contact>
    <investigator>
      <last_name>Ivo Iliev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUDr. I. Cierna Peterova s.r.o.</name>
      <address>
        <city>Brandýs Nad Labem</city>
        <zip>25001</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Cierna Peterova, MD</last_name>
      <phone>+420728100377</phone>
      <email>trnbrnl@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ivana Cierna Peterova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno, Dept of Klinika nemoci plicnich a tuberkulozy</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristian Brat, MD, PhD</last_name>
      <phone>+420775747176</phone>
      <email>brat.kristian@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Kristian Brat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EDUMED s.r.o.</name>
      <address>
        <city>Broumov</city>
        <zip>550 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Svarc, MD</last_name>
      <phone>+420774966570</phone>
      <email>temi@centrum.sk</email>
    </contact>
    <investigator>
      <last_name>Michal Svarc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUDr. Petr Pravda</name>
      <address>
        <city>Hlučín</city>
        <zip>74801</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Pravda, MD</last_name>
      <phone>+420608711683</phone>
      <email>pravda.petr@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Pravda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MediTrial s.r.o.</name>
      <address>
        <city>Jindřichův Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Kopecká, MD</last_name>
      <phone>+420380421700</phone>
      <email>kopecka.daniela@email.cz</email>
    </contact>
    <investigator>
      <last_name>Daniela Kopecká, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plicni ambulance Kralupy s.r.o.</name>
      <address>
        <city>Kralupy Nad Vltavou</city>
        <zip>278 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otakar Hokynar, MD</last_name>
      <phone>+420 724 982 803</phone>
      <email>hokynar.plicni.amb@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Otakar Hokynar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CEFISPIRO s.r.o.</name>
      <address>
        <city>Lovosice</city>
        <zip>41002</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Filipova, MD</last_name>
      <phone>+420725782819</phone>
      <email>pphilip@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Petra Filipova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odborná plicní ambulance Opava s.r.o.</name>
      <address>
        <city>Opava</city>
        <zip>74601</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zdenek Heralt, MD</last_name>
      <phone>+420722920784</phone>
      <email>heraltz@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Zdenek Heralt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DAWON spol. s.r.o., Plicni ambulance</name>
      <address>
        <city>Praha 4</city>
        <zip>149 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romana Davidova, MD</last_name>
      <phone>+420723233735</phone>
      <email>romanadavidova@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Romana Davidova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plicni centrum s.r.o.</name>
      <address>
        <city>Praha 5</city>
        <zip>15300</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irena Spasova, MD, PhD</last_name>
      <phone>+420723894174</phone>
      <email>spasovairena@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Irena Spasova, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUDr. Josef Veverka, Plicni ambulacne</name>
      <address>
        <city>Rokycany</city>
        <zip>33701</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Veverka, MD</last_name>
      <phone>+420371729310</phone>
      <email>veverka.rokycany@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Josef Veverka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plicni stredisko Teplice s.r.o.</name>
      <address>
        <city>Teplice</city>
        <zip>41501</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislav Holub, MD</last_name>
      <phone>+420777048663</phone>
      <email>stanislavholub@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Stanislav Holub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Trebic p.o., Dept of Plicni ambulance</name>
      <address>
        <city>Třebíč</city>
        <zip>674 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Schreiber, MD</last_name>
      <phone>+420606540635</phone>
      <email>jiri.a.schreiber@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jiri Schreiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Keller</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Keller, MD</last_name>
      <phone>+496946003681</phone>
      <email>ckeller-studien@praxis-ckeller.de</email>
    </contact>
    <investigator>
      <last_name>Claus Keller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Christian Schlenska</name>
      <address>
        <city>Peine</city>
        <state>Niedersachsen</state>
        <zip>31224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schlenska, MD</last_name>
      <phone>+49517177570</phone>
      <email>dr.schlenska@pneumologe-schlenska.de</email>
    </contact>
    <investigator>
      <last_name>Christian Schlenska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pneumologische Praxis Dr. Falk Brunner</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falk Brunner, MD</last_name>
      <phone>+493419113500</phone>
      <email>csfb@gmx.net</email>
    </contact>
    <investigator>
      <last_name>Falk Brunner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salvus-Klinische Studien GmbH.</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Deckelmann, MD</last_name>
      <phone>+493412460313</phone>
      <email>studien@dr-deckelmann.de</email>
    </contact>
    <investigator>
      <last_name>Regina Deckelmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>POIS Leipzig GbR, Pneumo-/onkologisch/internistisches Studienzentrum</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Gessner, MD</last_name>
      <phone>+4934160050650</phone>
      <email>ch.gessner@pois-le.de</email>
    </contact>
    <investigator>
      <last_name>Christian Gessner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KLB Gesundheitsforschung Luebeck GmbH; Praxis Dr. med. Jens Becker</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig Holstein</state>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Ludwig-Sengpiel, MD</last_name>
      <phone>+494517078300</phone>
      <email>a.ludwig@klb-healthresearch.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Ludwig-Sengpiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis an der Oper.</name>
      <address>
        <city>Berlin</city>
        <zip>10625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Lienert, MD</last_name>
      <phone>+49303421056</phone>
      <email>thomas.lienert@praxisanderoper.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Lienert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ballenberger, Freytag, Wenisch Institut für klinische Forschung</name>
      <address>
        <city>Neu Isenburg</city>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Ballenberger, MD</last_name>
      <phone>+49 6102 809710</phone>
      <email>ballenberger@bfw-institut.de</email>
    </contact>
    <investigator>
      <last_name>Sabine Ballenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens of Chest Diseases &quot;SOTIRIA&quot;, 7th Respiratory Clinic</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asimina Gaga, MD</last_name>
      <phone>+302107781720</phone>
      <email>elmoraitou@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Asimina Gaga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion, Pulmonary Clinic</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katerina Antoniou, MD</last_name>
      <phone>+302810392433</phone>
      <email>katerinaantoniou@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Katerina Antoniou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina, University Respiratory Clinic</name>
      <address>
        <city>Ioánnina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Kostikas, DMSc</last_name>
      <phone>+302651099266</phone>
      <email>ktkostikas@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Konstantinos Kostikas, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa, University Pulmonary Clinic</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Gourgoulianis, MD</last_name>
      <phone>+302410682785</phone>
      <email>kgourg@uth.gr</email>
    </contact>
    <investigator>
      <last_name>Konstantinos Gourgoulianis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinexpert Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronika Urbán, MD</last_name>
      <phone>+36(1)210-8139</phone>
      <email>nyugalomvolgy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Veronika Urbán, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szalay János Rendelőintézet Tüdőgyógyászati Szakrendelés</name>
      <address>
        <city>Hajdúnánás</city>
        <zip>4080</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edina Kurucz, MD</last_name>
      <phone>+36202656523</phone>
      <email>drkuruczedina@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Edina Kurucz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lumniczer Sandor Kórház és Rendelőintézet Tüdőgondozó</name>
      <address>
        <city>Kapuvár</city>
        <zip>9330</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ildiko Breining, MD</last_name>
      <phone>+36303854462</phone>
      <email>ildikobreining@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ildiko Breining, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Kórház és Rendelőintézet Monori Rendelőintézete</name>
      <address>
        <city>Monor</city>
        <zip>2200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltán Bende, MD</last_name>
      <phone>+36703713271</phone>
      <email>zoltan.bende@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Zoltán Bende, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolina Kórház-Rendelőintézet, Tüdőgyógyászat</name>
      <address>
        <city>Mosonmagyaróvár</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Unger, MD</last_name>
      <phone>+36 70 375 0011</phone>
      <email>ungerstudy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Erika Unger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Püspökladányi Egészségügyi Szolgáltató Nonprofit Kft.</name>
      <address>
        <city>Püspökladány</city>
        <zip>4150</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelli Kosztyu, MD</last_name>
      <phone>+3630405907</phone>
      <email>nellypharmanex@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nelli Kosztyu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Markusovszky Egyetemi Oktatókórház Tüdőgondozó</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsuzsanna Cseke, MD</last_name>
      <phone>+36303501020</phone>
      <email>csekezs@t-email.hu</email>
    </contact>
    <investigator>
      <last_name>Zsuzsanna Cseke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju Severance Christian Hospital</name>
      <address>
        <city>Wŏnju</city>
        <state>Gangwon-do</state>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk Joong Yong, MD</last_name>
      <phone>+82337410540</phone>
      <email>sjyong@yonsei.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Suk Joong Yong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Il Yoon, MD</last_name>
      <phone>+82317877036</phone>
      <email>dextro70@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ho Il Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwan Ho Lee, MD, PhD</last_name>
      <phone>+82526406501</phone>
      <email>ghlee@med.yu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Kwan Ho Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye Sook Choi, MD, PhD</last_name>
      <phone>+821089884452</phone>
      <email>maxymus72@daum.net</email>
    </contact>
    <investigator>
      <last_name>Hye Sook Choi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Joo Lee, MD</last_name>
      <phone>+8229206078</phone>
      <email>nanjung@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Eun Joo Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Ye Jung, MD</last_name>
      <phone>+821031412576</phone>
      <email>STOPYES@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Ji Ye Jung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sei Won Lee, MD</last_name>
      <phone>+82230103990</phone>
      <email>iseiwon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sei Won Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin Kook Rhee, MD, PhD</last_name>
      <phone>+82222586067</phone>
      <email>chinkook77@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chin Kook Rhee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Yeouido St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07345</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Kyu Yoon, MD</last_name>
      <phone>+82237792213</phone>
      <email>cmcyhg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hyoung Kyu Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne KERmed</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-231</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Bijata-Bronisz, MD, PhD</last_name>
      <phone>+48 601 681 594</phone>
      <email>renata.bijata-bronisz@kermed.pl</email>
    </contact>
    <investigator>
      <last_name>Renata Bijata-Bronisz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Chełmińska, MD, PhD</last_name>
      <phone>+48585844310</phone>
      <email>marta.chelminska@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Marta Chełmińska, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ Alergopneuma Sp. J. Marek Michnar I Wspólnicy</name>
      <address>
        <city>Lublin</city>
        <zip>20-089</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Michnar, MD, PhD</last_name>
      <phone>+48606659797</phone>
      <email>michnar@interia.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Michnar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Alergologii Sp. z o. o.</name>
      <address>
        <city>Lublin</city>
        <zip>20-552</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izabella Krupa-Borek, MD, PhD</last_name>
      <phone>+48814628882</phone>
      <email>izabella.kb@wp.pl</email>
    </contact>
    <investigator>
      <last_name>Izabella Krupa-Borek, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Grunwald</name>
      <address>
        <city>Poznań</city>
        <zip>60-369</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Kostrzewska, MD</last_name>
      <phone>+48618417061</phone>
      <email>magdalena.kostrzewska@cmgrunwald.com</email>
    </contact>
    <investigator>
      <last_name>Magdalena Kostrzewska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ETG Siedlce</name>
      <address>
        <city>Siedlce</city>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirosław Trzciński, MD</last_name>
      <phone>+48696147343</phone>
      <email>m.trzcinski@etg-network.com</email>
    </contact>
    <investigator>
      <last_name>Mirosław Trzciński, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NASZ LEKARZ Ośrodek Badań Klinicznych</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Trawińska, MD</last_name>
      <phone>+48563004380</phone>
      <email>e.trawinska@naszlekarz.pl</email>
    </contact>
    <investigator>
      <last_name>Ewa Trawińska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ETG Warszawa</name>
      <address>
        <city>Warsaw</city>
        <zip>02-793</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luiza Jonczak, MD, PhD</last_name>
      <phone>+48223702134</phone>
      <email>l.jonczak@etg-network.com</email>
    </contact>
    <investigator>
      <last_name>Luiza Jonczak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBHI &quot;Regional Clinical Hospital #3&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galina Ignatova, MD,PhD,DrMS</last_name>
      <phone>+73517426640</phone>
      <email>iglign@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Galina Ignatova, MD,PhD,DrMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LLC MA New Hospital</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Leshchenko, MD,PhD,DrMS</last_name>
      <phone>+73432424913</phone>
      <email>leshchenkoiv@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Igor Leshchenko, MD,PhD,DrMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Scientific-research Institute for Complex Problems of cardiovascular disease&quot;</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeny Bazdyrev, MD, PhD</last_name>
      <phone>+79069249350</phone>
      <email>edb624@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Evgeny Bazdyrev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBIH of Novosibirsk Region &quot;Clinical Emergency Hospital #2&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Goncharova, MD</last_name>
      <phone>+73832661382</phone>
      <email>gon-svetlana@ya.ru</email>
    </contact>
    <investigator>
      <last_name>Svetlana Goncharova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPb SBHI &quot;Vvedenskaya hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191180</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Kuzubova, MD,PhD,DrMS</last_name>
      <phone>+78123386616</phone>
      <email>kuzubova@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Natalia Kuzubova, MD,PhD,DrMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pavlov First Saint Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vasiliy Trofimov, MD,PhD,DrMS</last_name>
      <phone>+78122345509</phone>
      <email>trofvi@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Vasiliy Trofimov, MD,PhD,DrMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPb SBIH &quot;City Hospital # 40 of Kurortnyi region&quot;</name>
      <address>
        <city>Sestroretsk</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina Agafina, MD, PhD</last_name>
      <phone>+78124353750</phone>
      <email>a.agafina@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Alina Agafina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBHI of Yaroslavl Region &quot;Clinical Hospital # 2&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>1500030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrey Arshinov, MD,PhD,DrMS</last_name>
      <phone>+74852445404</phone>
      <email>a_arshinov@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Andrey Arshinov, MD,PhD,DrMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SBHI of Yaroslavl Region &quot;Clinical Hospital # 2&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Khokhlov, MD,PhD,DrMS</last_name>
      <phone>+74852465148</phone>
      <email>alekskhokhlov@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Alexander Khokhlov, MD,PhD,DrMS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnica s poliklinikou Sv. Jakuba, n.o. Bardejov</name>
      <address>
        <city>Bardejov</city>
        <zip>08501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Lescisinova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Helena Lescisinova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspiro, s.r.o.</name>
      <address>
        <city>Humenné</city>
        <zip>06601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Golubov, MD</last_name>
      <phone>+421577706205</phone>
      <email>agolubov0904@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Golubov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plucna ambulancia Hrebenar, s.r.o.</name>
      <address>
        <city>Spišská Nová Ves</city>
        <zip>05201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slavomir Hrebenar, MD</last_name>
      <phone>+421534410442</phone>
      <email>slavomir.hrebenar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Slavomir Hrebenar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

